By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Celyad (Formally Known as Cardio3 BioSciences) 

Parc de L’Alliance
9, Boulevard de France
Braine - L’Alleud    1420  Belgium
Phone: 32-2-790-35-30 Fax: 32-2-790-35-35



Company News
Celyad Announces Third Quarter 2015 Business Update 11/19/2015 8:10:51 AM
Celyad Successfully Completes 30-Day Safety Follow-Up Of First Patient Cohort In NKG2D CAR T-Cell Phase I Trial 11/10/2015 7:38:47 AM
First US Patent Covering Allogeneic Chimeric Antigen Receptor T Cells ("CAR-T") Modified To Reduce Immunogenicity Is Awarded To Celyad 10/23/2015 8:06:05 AM
Celyad Announces the Appointment Of Dr. Frederic Lehmann As Vice President Immuno-Oncology 9/15/2015 6:39:44 AM
Celyad Announces The Appointment Of Dr. Debasish Roychowdhury As Independent Director 9/4/2015 7:25:38 AM
Celyad Announces Commercial License Agreement for C-Cure In Greater China 8/31/2015 7:13:33 AM
Celyad Reports First Half 2015 Financial Results And Operational Progress 8/25/2015 7:12:03 AM
Celyad Announces Details Of Upcoming Half Year 2015 Financial Results 8/12/2015 12:29:54 PM
Celyad Completes Final Patient Infusion In CHART-1 Phase III Trial 8/3/2015 7:09:48 AM
Celyad Announces Closing of Its Global Offering 6/24/2015 10:49:06 AM